Ilia Yu. Feidorov

Ilia Yu. Feidorov

Auto-generated profile, based on publicly available information

Ilia Yu. Feidorov

Loginov Moscow Clinical Scientific Center

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
AMAlesia Maluchenko
Alesia Maluchenko
DMDenis Maksimov
Denis Maksimov
ZAZoia Antysheva
Zoia Antysheva
JKJulia Krupinova
Julia Krupinova
EAEkaterina Avsievich
Ekaterina Avsievich
PVPavel Volchkov
Pavel Volchkov
Pancreatic neuroendocrine tumors (NETs) are rare well-differentiated neoplasms with limited therapeutic options and unknown cells of origin. The current classification of pancreatic neuroendocrine tumors is based on proliferative grading, and guides therapeutic strategies, however, tumors within grades exhibit profound heterogeneity in clinical manifestation and outcome. Manifold studies have highlighted intra-patient differences in tumors at the genetic and transcriptomic levels. Molecular classification might become an alternative or complementary basis for treatment decisions and reflect tumor biology, actionable cellular processes. Here, we provide a comprehensive review of genomic, transcriptomic, proteomic and epigenomic studies of pancreatic NETs to elucidate patterns shared between proposed subtypes that could form a foundation for new classification. We denote four NET subtypes with distinct molecular features, which were consistently reproduced using various omics technologies.

14 December 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
EAEkaterina Avsievich
Ekaterina Avsievich
DSDiana Salimgereeva
Diana Salimgereeva
AMAlesia Maluchenko
Alesia Maluchenko
ZAZoia Antysheva
Zoia Antysheva
MVMark Voloshin
Mark Voloshin
JKJulia Krupinova
Julia Krupinova
Background: Neuroendocrine neoplasms are a rare and heterogeneous group of neoplasms. Small-sized (≤2 cm) pancreatic neuroendocrine tumors (PanNETs) are of particular interest as they are often associated with aggressive behavior, with no specific prognostic or progression markers. Methods: This article describes a clinical case characterized by a progressive growth of nonfunctional PanNET requiring surgical treatment in a patient with a germline FANCD2 mutation, previously not reported in PanNETs. The patient underwent whole exome sequencing and single-cell RNA sequencing. Results: The patient underwent surgical treatment. We confirmed the presence of the germline mutation FANCD2 and also detected the germline mutation WNT10A. The cellular composition of the PanNET was analyzed using single-cell sequencing, and the main cell clusters were identified. We analyzed the tumor genomics, and used the data to define the effect the germline FANCD2 mutation had. Conclusions: Analysis of the mutational status of patients with PanNET may provide additional data that may influence treatment tactics, refine the plan for monitoring such patients, and provide more information about the pathogenesis of PanNET. PanNET research using scRNA-seq data may help in predicting the effect of therapy on neuroendocrine cells with FANCD2 mutations.

11 March 2023 in Endocrine Surgery
Verified
Journal Article
Open access
PDF file
DSDiana Salimgereeva
Diana Salimgereeva
IFI. Y. Feidorov
I. Y. Feidorov
IKI. E. Khatkov
I. E. Khatkov
ИФИ. Ю. Фейдоров
И. Ю. Фейдоров
The availability of modern high-precision diagnostic methods increased the detection rate of pancreatic neuroendocrine neoplasia (pNEN). There is no doubt concerning the necessity of surgical treatment for localized functioning tumors, whilecurrently there is no objective way to choose the tactic for non-functioning asymptomatic neuroendocrine tumors of the pancreas (pNET) with the exception of the tumor size.Treatment tactics for non-functioning asymptomatic T1 neuroendocrine tumors (less 2 cm in size) are debatable. According to literature surgical treatment for lesions less than 2 cm does not always increase survival. In the same time even in high-volume centers pancreatic surgery shows high morbidity and mortality rate. Prospective randomized trials comparing surveillance and operative treatment are not published yet, as far as authors concerned. International guidelines answer the question of treatment such neoplasms ambiguously, while national Russian recommendations do not cover the topic. Guidelines are based on heterogeneous retrospective studies; therefore, the aim of scientific research is to determine reliable criteria for patient selection for dynamic observation or surgical treatment.This article provides an overview of 60 scientific publications covering the problem.

25 June 2025 in Russian Journal of Gastroenterology, Hepatology, Coloproctology
Verified
Journal Article
Open access
PDF file
IKI. E. Khatkov
I. E. Khatkov
DSDiana Salimgereeva
Diana Salimgereeva
IFI. Yu. Feidorov
I. Yu. Feidorov
AKA. A. Konyakhina
A. A. Konyakhina
APA. L. Petrova
A. L. Petrova
ИФИ. Ю. Фейдоров
И. Ю. Фейдоров
Aim: to evaluate results of follow-up of patients with pancreatic non-functioning neuroendocrine tumors of the stage T1–T2 using a medical registry.Materials and methods. A retrospective analysis of the medical registry data of the Loginov Moscow Scientific Center was conducted, which included 312 patients with pancreatic neuroendocrine tumors from 2014 to 2023. Observation was recommended for 115 (36.9 %) patients. The inclusion criteria: diagnosis of pancreatic neuroendocrine tumor; non-functioning tumor status; asymptomatic disease; tumor size less than 3 cm; patient’s consent. The exclusion criteria were patient’s refusal of observation; tumor growth of more than 3 mm/year of observation; appearance of disease symptoms. Based on the registry data, gender and age of patients, size and location of tumors, TNM stage, tumor growth dynamics (mm/year), biochemical markers of neuroendocrine tumors, and the presence of concomitant pathology were studied. Whole genome sequencing was performed on 53 patients with first diagnosed pancreatic neuroendocrine tumors.Results. Six patients (5.2 %) were excluded from the study: three refused to be observed, three demonstrated tumor growth. 109 patients diagnosed with non-functioning pancreatic neuroendocrine tumor were included in the analysis: 78 (71.6 %) women and 31 (28.4 %) men aged from 22 to 86 years (58.5 ± 10.8 years) at the time of presentation. The median follow-up time was 34.0 (2.0–86.0) months. The most common location of tumors was in the head of the pancreas — 45.5 % (n = 51). Of the 109 patients observed, 103 were diagnosed with stage T1 tumors (94.5 %), 6 — with T2 (5.5 %). The average tumor size was 11.9 ± 3.8 mm (3.1–29.0 mm) (n = 118). An increase in biochemical markers of neuroendocrine tumors (gastrin, chromogranin A) was associated with atrophic gastritis. Germline mutations were detected in 24.0 % of patients (n = 12). The most common mutations in the sample were the CHEK2 gene (n = 4).Conclusions. According to the registry data, active observation is an acceptable tactic for managing patients with T1 non-functioning pancreatic neuroendocrine tumors. Likely it is not the size of the tumor but its growth rate that has prognostic significance, and therefore a protocol for monitoring this group of patients is required. The effect of estrogens on tumor growth inhibition and the role of CHEK2 gene mutations are perspectives for future research.

31 December 2020 in Journal of Modern Oncology
Verified
Journal Article
Open access
PDF file
AAArif K. Allakhverdiev
Arif K. Allakhverdiev
NMNataliya A. Malkina
Nataliya A. Malkina
KNKarina K. Noskova
Karina K. Noskova
VGVyacheslav N. Grinevich
Vyacheslav N. Grinevich
IFIlia Yu. Feidorov
Ilia Yu. Feidorov
ФЮФейдоров Илья Юрьевич
Фейдоров Илья Юрьевич
The article presents a clinical case of a prolonged course of gastrointestinal ulcer disease, followed by dysphagia. During the examination, severe hyperparathyroidism was revealed, which subsequently prompted a diagnostic search for a parathyroid adenoma, which is the cause of hyperathyroidism in 8085% of cases. With instrumental methods of research, the cause of the main complaint is dysphagia, a formation in the posterior upper mediastinum up to 5 cm, compressing the esophagus. With transoesophageal aspiration biopsy (EUS-TYPE). The cytological picture is similar to the thyroid epithelium with part of the oncocytic differentiation. In an immunological study, lavage for parathyroid hormone showed high expression. Scintigraphy with Tc-99m pertechnetate revealed the exact topic of the formation of the parathyroid gland in the posterior mediastinum an atypical location. Surgical treatment was performed in the amount of thoracoscopic removal of the mediastinal tumor. The radical nature of the surgical intervention was confirmed by laboratory. Serum PTH levels decreased significantly. Upon receipt of the morphological conclusion, reliable data on malignant damage to the parathyroid gland were obtained. Subsequent treatment of the patient consisted in the correction of severe hypercalcemia in the postoperative period by prescribing denosumab, which led to the stabilization of the patients condition.

5 March 2024 in Journal of Modern Oncology
Verified
Journal Article
Open access
PDF file
OMOlga R. Magamedova
Olga R. Magamedova
LOLiana V. Oganesyan
Liana V. Oganesyan
PFPolina S. Feoktistova
Polina S. Feoktistova
IFIlia Yu. Feidorov
Ilia Yu. Feidorov
ФЮФейдоров Илья Юрьевич
Фейдоров Илья Юрьевич
Adrenocortical carcinoma is an orphan disease with an annual incidence of 1–2 cases per 1 million adults. The median overall survival (OS) is only 17 months. Definitive surgery increases the median OS to 28 months. The article presents a clinical case of a patient with hormonally active adrenocortical carcinoma of the right adrenal gland, accompanied by tumor thrombosis of the inferior vena cava extending to the right atrium. Surgery was performed for the thrombus removal. A wrong initial diagnosis led to a delay in adjuvant mitotane therapy. The recurrence of the disease was treated with mitotane and somatostatin analogues, considering the high expression of somatostatin receptors in the tumor. At the second progression, the patient was switched to chemotherapy in the EDP regimen combined with continued therapy with mitotane and octreotide, resulting in long-term control of the disease. The time without progression and OS were 18 and 42 months, respectively.